QuintilesIMS’s Cristina Oliva talks to pharmaphorum about her personal highlights from this year’s European Society for Medical Oncology (ESMO) congress in Copenhagen.
The booming interest in new targeted therapies represents a changing of the guard in cancer treatment, from the former one-size-fits-all approach to a more personalised methodology.
BMS’s Opdivo and Merck’s Keytruda have been the sole PD-1 immunotherapies for the last two years, but Roche’s Tecentriq gained approval in May this year in urothelial carcinoma, a cancer of
Day three at the European Society for Medical Oncology 2016 congress belonged to Merck & Co., and may well be seen as a hugely significant day in the future of lung cancer treatment.
Japanese pharma group Eisai says it is battling a ransomware attack that was launched last weekend and has resulted in some of its servers becoming encrypted.
Health systems globally have reached a critical inflexion point, where ageing populations and tightening budgets mean we can no longer continue to purely treat late-stage symptomatic diseas